

DESIGN AND MECHANISTIC EVALUATION OF NOVEL PORE-REGULATED POLYMER MATRICES FOR TRANSMUCOSAL DRUG DELIVERY



Oluwatoyin Ayotomilola Adeleke

A thesis submitted to the Faculty of Health Sciences, University of the Witwatersrand,
in fulfillment of the requirements for the degree of Doctor of Philosophy

Supervisor:

Professor Viness Pillay
University of the Witwatersrand, Department of Pharmacy and Pharmacology,
Johannesburg, South Africa

2011

DECLARATION

I, Oluwatoyin A. Adeleke (**Nee Kolawole**) declare that this thesis is my own work. It is being submitted for the degree of Doctor of Philosophy in the Department of Pharmacy and Pharmacology, Faculty of Health Sciences at the University of the Witwatersrand, Johannesburg, South Africa. It has not been submitted before for any degree or examination at this or any other University. The abstracts and copy of paper(s) included are part of this work.

.....

Signature

.....

Date

RESEARCH OUTPUTS ARISING FROM THIS WORK

CONFERENCE PROCEEDINGS

1. A pore-regulated composite matrix for prolonged transmucosal drug delivery by Oluwatoyin A. Kolawole, Viness Pillay, Yahya E. Choonara and Lisa C. du Toit at the research day and faculty postgrad expo of the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 2008.
2. Influence of formulation variables on the porosity, bioadhesion and drug release characteristics of a pore-regulated matrix by Oluwatoyin A. Kolawole, Viness Pillay, Yahya E. Choonara and Lisa C. du Toit at the 28th Annual conference of the Academy of Pharmaceutical Sciences, Magaleisburg, South Africa, 2008.
3. Physicochemical analysis of the formulation approach employed in constructing a porosity-controlled drug delivery system by Oluwatoyin A. Kolawole, Viness Pillay, Yahya E. Choonara and Lisa C. du Toit at the 28th Annual conference of the Academy of Pharmaceutical Sciences, Magaleisburg, South Africa, 2008.
4. A bioadhesive porous matrix for prolonged transmucosal delivery of phenytoin sodium through porcine buccal mucosa by Oluwatoyin A. Kolawole, Viness Pillay, Yahya E. Choonara and Lisa C. du Toit at the 28th Annual conference of the Academy of Pharmaceutical Sciences, Magaleisburg, South Africa, 2008.
5. Design and characterization of a pore-regulated matrix for transmucosal drug delivery by Oluwatoyin A. Kolawole, Viness Pillay, Yahya E. Choonara, Lisa C. du Toit and Valence M K. Ndesendo at the American Association of Pharmaceutical Scientists annual meeting and exposition, Atlanta World Congress Centre, Atlanta, Georgia, United States of America, 2008.
6. The influence of pore morphology on the matrix integrity, drug loading and drug release from a porous delivery platform by Oluwatoyin A. Kolawole, Viness Pillay, Yahya E. Choonara, Lisa C. du Toit and Valence M K. Ndesendo at the American Association of

Pharmaceutical Scientists annual meeting and exposition, Atlanta World Congress Centre, Atlanta, Georgia, United States of America, 2008.

7. *In vitro* and *in vivo* evaluation of a bioadhesive porous composite for the sustained transbuccal delivery of phenytoin by Oluwatoyin A. Adeleke (**Nee Kolawole**), Viness Pillay, Yahya E. Choonara and Lisa C. du Toit at the American Association of Pharmaceutical Scientists, Los Angeles Convention Centre, Los Angeles, California, United States of America, 2009.

8. Histomorphological evaluation of a mucoadhesive, porous matrix for controlled transbuccal drug delivery by Oluwatoyin A. Adeleke (**Nee Kolawole**), Viness Pillay, Yahya E. Choonara and Lisa C. du Toit at the 5th International Conference on Pharmaceutical and Pharmacological Sciences, Potchefstroom, South Africa, 2009.

PUBLICATION

Adeleke O.A. (**Nee Kolawole**), Pillay, V., du Toit, L.C. and Chonara Y.E. (2010). Construction and *in vitro* characterization of an optimized porosity-enabled amalgamated matrix for sustained transbuccal drug delivery. *International Journal of Pharmaceutics*, 391:79-89.

PATENT APPLICATION

A transmucosal delivery system by Oluwatoyin A. Adeleke, Viness Pillay and Yahya E. Choonara, South African Patents and Trade Mark Office, Patent Application Filed in 2008; *awaiting priority date*.

ABSTRACT

This thesis focuses on the fabrication, optimization and in vitro, ex vivo as well as in vivo testing/characterization of novel pore-regulated polymer matrices (P-RPM) for sustained transmucosal (transbuccal) drug delivery application employing phenytoin sodium (solubility: 100mg/mL at 25°C and log P = 2.14) and carbamazepine (solubility: 0.01mg/mL at 25°C and log P = 2.93) as model drugs. A simple and optimally efficient interphase, co-particulate-co-solvent homogenization technique coupled with pre-freezing and lyophilization were employed for the fabrication of the P-RPM formulations. The construction and optimization of these novel P-RPM formulations were guided through the statistical and mathematical principles of high performance experimental design approaches. A general introduction to the concept of this thesis is presented at the beginning. The initial phase of this investigation employed the Box-Behnken experimental design to demonstrate the effects of varying formulation variables on the physicochemical and physicomechanical performances of the P-RPMs as well as to statistically optimize these properties for the intended transbuccal drug delivery application. The impact of pore-regulation, measured as average pore diameter and cumulative surface area of pores, on the magnitude of relevant physicochemical and physicomechanical properties of the P-RPMs was also evaluated using linear/non-linear mathematical expressions. Besides, the effects of the differences in the physicochemical properties of phenytoin sodium and carbamazepine loaded unto the optimized P-RPMs revealed their versatility and robustness. In vivo studies using animal models showed the potential of the optimized P-RPM formulations to effectively initiate and sustain transbuccal permeation which regulates the systemic absorption of drug molecules as visualized by outcomes from the quantitative and qualitative assessments of collected blood plasma samples. Furthermore, comparisons of the in vitro release and in vivo absorption characteristics of phenytoin sodium (PS) and carbamazepine (CBZ) from the optimized P-RPM formulation with the comparator products namely Epanutin[®] and Tegretol[®]CR respectively showed the potential of the P-RPM formulations to attain higher and more controlled release trends at lower drug loading levels without any dose dumping. The non-compartmental PK-PD modeling process further revealed the differences in the performances of the PS or CBZ loaded P-RPM formulations in comparison with their respective comparator products. The developed point-to-point level A IVIVC model for both the PS and CBZ loaded P-RPM formulations displayed a linear trend ($R^2 > 0.9$) indicating the possibility of applying respective in vitro dissolution profiles as substitutes for bioequivalency testing for this set of formulations. Histological and cytological investigations confirmed that both the placebo and drug loaded P-RPM formulations had insignificant toxic and irritable effects on the buccal mucosal specimens and cell cultures evaluated indicating that the optimized P-RPMs are potentially biocompatible. Experimental and computational modeling approaches explained the mechanisms of formation of the P-RPM formulation to be based upon structurally, non-destructive physical and mechanical transitions and the mechanism of action to be due to the disruption of the ordered porous matrix structure by physical processes such as disentangling, matrix swelling, plasticization and dissolution as a result of hydration. Preliminary assessments of the impacts of scale-up processes and environmental storage conditions on the stability of the optimized P-RPM formulations suggested that scale-up processes did not significantly alter the physicochemical and physicomechanical performances of these formulations and that they are most stable at conditions with regulated humidity levels, light exposure and room temperature fluctuations.

ACKNOWLEDGEMENTS

I sincerely acknowledge the invaluable role that my supervisor, Professor Viness Pillay, played in ensuring the successful completion of this research project. I would like to thank him with a grateful heart for the consistent support, care, guidance, fatherly counsel, patience and discipline which he displayed during the course of the study. I appreciate him for the priceless knowledge that he imparted in me over the years. Prof, I truly thank you very much for being there all the way through and making me a better person/researcher. I will always remember every moment I spent with you for good.

I also acknowledge the great contribution of my Head of Department, Professor Michael P. Danckwerts to my success. Thank you so much for your encouraging words and ever-willing attitude of support and assistance towards me. I appreciate you sir.

I would like to thank Dr Yahya Choonara and Ms Lisa du Toit, for their willingness to assist me always. I am sincerely grateful for all your efforts.

To my husband, Mr. Adewale Adeleke, thank you so much my love for all that you have been to me. Words can never be used to express the magnitude of love, care, support, and patience which you have shown me. Thank you so much for those wise words of advice and encouragement as well as tireless prayers. I sincerely thank the Almighty God for the wonder of your being and I am grateful for the privilege He gave me to be united with you. Your presence has impacted my life greatly and positively and has made me a much better individual than I ever thought I could be. I genuinely appreciate your efforts.

To my precious gifts from God, Anjolaoluwa and Oluwakanyinsola Adeleke, thank you very much. Your gently, innocent smile and kind gestures gave me strength to persevere even when there seemed like there was no hope. I thank the Almighty God for giving me such wonderful gifts like you both to lighten my path when all seemed dark, discouraging and impossible.

I am indeed indebted to my great and wonderful brothers, Ajibola, Ayoyinka and Ayokunle Kolawole as well as my loving and caring parents, Ibiyayo and Ayowole Kolawole, for their enduring love, care, support, understanding, patience and consistent prayers. I thank God for the gift of these precious individuals. I love and appreciate you all.

To my relatives and friends in South Africa and loved ones back home (Nigeria), thanks a great deal for your love, assistance, never-tiring support, prayers, and words of knowledge all the way through.

My special appreciation goes to all members of staff, fellow students and colleagues in the Department of Pharmacy and Pharmacology, University of the Witwatersrand, Johannesburg for their assistance, self-sacrifice and friendship. I thank you all for accepting me for who I am, building me into a better person and making my stay in the Department and South Africa worthwhile. I hold you all in high esteem and pray that the Almighty God rewards you accordingly.

To all members of the Central Animal Services (CAS) of the University of the Witwatersrand, Johannesburg, thank you so much for making the hectic and dreadful moments of performing the animal studies an interesting one for me. I am sincerely grateful.

A special thank you goes to Dr Haijera Davids of the Nelson Mandela Metropolitan University, Port Elizabeth for her assistance with the cytotoxicity assay.

The Medical Research Council (MRC), University of the Witwatersrand, TATA Africa, Biotechnology Partnerships and Development (BioPAD) of South Africa as well as the Ekiti State Scholarship Board, Nigeria are hereby acknowledged for award of scholarship and research funding.

Above all, I give all thanks, praise and adoration to the Almighty God who is the lover of my soul and the One that sustains my life. Thank you, Lord Jesus, for the grace, mercy, wisdom, strength to persevere, immeasurable love, deliverance and constant faithfulness which I experienced by walking this road with You. I adore you my Lord, Master, Author

and Finisher of my faith. Thank you so much for taking all the Glory for this research work. In my nothingness, You made me something. You are worthy to be praised my Lord and my all. My Lord Jesus Christ, you are everything to me and I thank You so much for without You I am a nobody. I was only able to complete this task because the Lord strengthened me and to Him alone I give the Glory, Honor and Adoration.

DEDICATION

This thesis is dedicated to my Lord, Saviour and best friend, Jesus Christ, for He is indeed my source of inspiration.

ANIMAL ETHICS DECLARATION

I, Oluwatoyin Ayotomilola Adeleke (**Nee Kolawole**) hereby confirm that the study entitled 'Design and mechanistic evaluation of novel pore-regulated polymer matrices for transmucosal drug delivery' received the approval from the Animal Ethics Committee of the University of the Witwatersrand with ethics clearance number AESC 2007/42/05.

TABLE OF CONTENTS

1.0.	General Literature Background, Rationale and Motivation, Technology Applied and Objectives for this Study	Page
1.1.	Background: Polymeric drug delivery	2
1.2.	Porous structured drug delivery matrices: Definitions and physical properties	4
1.3.	Drug delivery and biomedical applications of porous structured matrices	5
1.3.1.	Biological tissue scaffolds	6
1.3.2.	Implantable devices	6
1.3.3.	Optical devices	7
1.3.4.	Hydrogels	7
1.3.5.	Ceramics	7
1.3.6.	Biocomposites	8
1.3.7.	Sponges	8
1.3.8.	Microcapsules	9
1.3.9.	Wafers	9
1.3.10.	Membranes	10
1.3.11.	Nanoparticles	10
1.3.12.	Tablets	10
1.3.13.	Bio-package	11
1.3.14.	Foams	11
1.3.15.	Miscellaneous	11
1.4.	Transmucosal drug delivery	12
1.5.	The buccal mucosa: The selected model for this study	13
1.6.	Rationale and motivation for this study	15
1.6.1.	The model drugs employed: Rationale for selection	16
1.7.	Technological processes applied in this study	18
1.8.	Aim and objectives of the study	19
1.9.	Overview of this thesis	21
1.10	Concluding remarks	23
2.0.	Application of the Box-Behnken Experimental Design to the Construction, Mechanistic Evaluation and Optimization of the Pore-Regulated Polymer Matrices for Sustained Transbuccal Drug Delivery	
2.1.	Introduction	25

2.2.	Experimental section	27
2.2.1.	Materials	27
2.2.2.	Preparation of the pore-regulated polymer matrices (P-RPMs) in accordance with the Box-Behnken experimental design template	27
2.2.3.	Physical examination of the P-RPMs	31
2.2.4.	Evaluating the <i>in vitro</i> drug release behaviour of the P-RPMs	31
2.2.5.	Computation of the percentage drug loading capacity	32
2.2.6.	<i>Ex vivo</i> permeation studies utilizing the porcine buccal mucosa	32
2.2.6.1.	Tissue collection and preservation	32
2.2.6.2.	Preparation of the porcine buccal tissue specimen for permeation studies	33
2.2.7.	<i>Ex vivo</i> assessment of bioadhesive capacity using porcine buccal mucosa	34
2.2.8.	Matrix porosity analyses	35
2.2.8.1.	Qualitative evaluation of matrix porosity	35
2.2.8.2.	Qualitative porosimetric analysis	36
2.2.9.	Surface morphological characterization of the P-RPMs	37
2.2.10.	Rheological investigations of the homogenous co-particulate blends	37
2.2.11.	Measurement of the physicommechanical strength of the P-RPMs	37
2.2.12.	Preparation of calibration curves for PS in simulated saliva (pH 6.8) and simulated plasma (pH 7.4)	39
2.2.13.	Constrained statistical optimization	39
2.2.14.	Evaluation of the impact of pore-regulation on relevant physical quantities using a mathematical approach	41
2.3.	Results and discussion	42
2.3.1.	Physical appearance and weight variability	42
2.3.2.	Drug release from the matrices	43
2.3.3.	Drug loading capacity of the P-RPMs	47
2.3.4.	Extent of permeation of drug molecules through the porcine buccal mucosa	47
2.3.5.	<i>Ex vivo</i> bioadhesion testing	51
2.3.6.	Measurement of matrix porosity	51
2.3.6.1.	Qualitative measurement of matrix porosity	51
2.3.6.2.	Quantitative porosimetric analysis of matrices	53
2.3.7.	Examination of the surface morphologies of the P-RPMs	56
2.3.8.	Elucidation of rheological behaviour of the homogenous co-particulate blends	58
2.3.9.	Determination of physicommechanical parameters by textural analysis	61
2.3.10.	Preparation and assessment of the optimized P-RPM formulation	62
2.3.11.	Determination of the relationship between the parameters of pore-	64

	regulation and related physicochemical and physicomechanical properties	
2.4.	Concluding remarks	68
3.0.	Characterization and Investigation of the Versatility and Robustness of the Optimized Pore-Regulated Polymer Matrix Formulation Utilizing Phenytoin Sodium and Carbamazepine as Model Drugs	
3.1.	Introduction	71
3.2.	Experimental section	72
3.2.1.	Materials	72
3.2.2.	Fabrication of the optimized P-RPM formulation	72
3.2.3.	Evaluation of the physicochemical properties	73
3.2.4.	Measurement of physicomechanical parameters	73
3.2.5.	Preparation of calibration curves for PS and CBZ in simulated saliva and plasma	73
3.2.6.	Treatment of <i>in vitro</i> drug release	73
3.2.6.1.	Model-dependent approach	74
3.2.6.2.	Model-independent technique	75
3.2.7.	Analysis of <i>ex vivo</i> permeation data	76
3.2.8.	Comparison of the dissolution patterns of the PS and CBZ from the optimized P-RPM formulation with their commercially available counterparts	76
3.2.8.1.	Evaluation of drug release behaviour	76
3.2.8.2.	Preparation of calibration curves of PS and CBZ in the pH 6.8. and 1.2 phosphate buffered media	77
3.3.	Results and discussion	79
3.3.1.	Systematic characterization and comparison of the physicochemical properties of the PS and CBZ loaded optimized P-RPM formulations	79
3.3.1.1.	Physical appearance and weight	79
3.3.1.2.	Drug loading capacity, <i>ex vivo</i> bioadhesivity, quantitative matrix porosity and rheological parameters	79
3.3.1.3.	Examination of the surface porous structure	81
3.3.1.4.	<i>In vitro</i> drug release behaviour	82
3.3.1.4.1.	Comparison of drug release performance of the PS and CBZ loaded P-RPM formulations	82
3.3.1.5.	<i>Ex vivo</i> drug permeation	83
3.3.2.	Assessment of physicomechanical properties by textural analysis	87
3.3.3.	Comparing the <i>in vitro</i> release characteristics of the PS or CBZ loaded P-	87

	RPM formulations with the commercially available products	
3.4.	Concluding remarks	90
4.0.	Quantitative and Qualitative Assessments of the <i>In Vivo</i> Drug Plasma Levels Subsequent to the Administration of the Optimized Pore-Regulated Polymer Matrix Formulations and the Pharmacokinetic and Pharmacodynamic Modeling of the Generated Data	
4.1.	Introduction	92
4.2.	Experimental section	94
4.2.1.	Materials	94
4.2.2.	Quantitative evaluation of <i>in vivo</i> drug absorption employing the optimized P-RPM formulations	95
4.2.2.1.	Grouping of animals and procedure for <i>in vivo</i> studies	95
4.2.2.2.	Quantitative analysis: Instrumentation and chromatographic conditions	97
4.2.2.3.	Preparation of standard solutions and calibration curves for PS and CBZ	99
4.2.2.4.	The drug extraction procedure	100
4.2.3.	Qualitative evaluation of plasma samples using the Fourier Transform Infra Red Spectroscopy (FTIR)	101
4.2.4.	PK-PD modeling of the <i>in vivo</i> drug absorption data employing non-compartmental algorithms	101
4.2.4.1	Model selection and configuration	101
4.2.4.2.	Algorithm selection for PK-PD modeling	103
4.2.4.3.	Computation of salient PK-PD parameters	104
4.2.4.4.	Bioequivalence analysis	105
4.2.4.5.	Determination of <i>in vitro-in vivo</i> correlation	105
4.3.	Results and discussion	105
4.3.1.	<i>In vivo</i> plasma levels of PS and CBZ and comparison with the conventional formulations	105
4.3.1.1.	Calibration curves of PS and CBZ	105
4.3.1.2.	Plasma-concentration time curves for the different formulations	108
4.3.2.	Elucidation of the performed PK-PD modeling	110
4.3.2.1.	Evaluation of model validity and summarized comparative assessment of non-compartmental PK-PD model parameters for the tested formulations	110
4.3.2.2.	Relative bioavailability analysis	114
4.3.2.3.	<i>In vitro-In vivo</i> correlation	116
4.3.3.	Qualitative analysis of <i>in vivo</i> drug plasma levels of PS and CBZ from the P-RPM formulations	117

4.3.3.1.	Phenytoin sodium	117
4.3.3.2.	Carbamazepine	119
4.4.	Concluding Remarks	120
5.0.	Investigating the Biocompatibility and Toxicity of the Optimized, Drug Loaded Pore-Regulated Polymer Matrices Employing Histomorphological and Cytological Analyses	
5.1.	Introduction	123
5.2.	Experimental section	125
5.2.1.	Materials	125
5.2.2.	Histological studies to assess the potential toxicity and biocompatibility of the newly constructed P-RPM formulations	125
5.2.3.	Cytotoxicity studies	126
5.2.3.1.	Preparation of test formulations and description of controls	126
5.2.3.2.	Routine cell culture maintenance	126
5.2.3.3.	Trypsinization, cell counting and seeding of cells	126
5.2.3.4.	Colorimetric MTT assay	127
5.2.3.5.	Preparation of calibration curve and computation of viable cell number	127
5.3.	Result and discussion	129
5.3.1.	Histomorphological evaluation of the buccal mucosal tissue specimens post administration of the optimized P-RPM formulations	129
5.3.2.	Cytotoxicity assay	133
5.4.	Concluding remarks	135
6.0.	Elucidation of Probable Mechanisms of Configuration and Performance of the Newly Fabricated Pore-Regulated Polymer Matrix Formulation Using Experimental And Computational Molecular Modeling Techniques	
6.1.	Introduction	137
6.2.	Experimental section	139
6.2.1.	Materials	139
6.2.2.	Experimental approach to the elucidation of the mechanisms of configuration and function of the P-RPM formulation	139
6.2.2.1.	Mechanism of configuration/formation	139
6.2.2.1.1.	Assessment of possible structural transitions during matrix preparation	139
6.2.2.1.2.	Determination of thermal behaviour using differential scanning calorimetry	139
6.2.2.1.3.	Changes in sample weight before and after lyophilization	140

6.2.2.1.4.	Evaluation of the physicochemical texture	140
6.2.2.2.	Mechanism of function/action	141
6.2.2.2.1.	Infrared spectrophotometry	141
6.2.2.2.2.	Scanning electron microscopy	141
6.2.2.2.3.	Gravimetric analysis	142
6.2.2.2.4.	Textural analysis	142
6.2.3.	Prediction of the underlying mechanisms of configuration and function of the P-RPM with computational modeling	142
6.3.	Result and discussion	142
6.3.1.	Experimental techniques for the explication of fundamental mechanisms of formation and action of the P-RPM formulation	142
6.3.1.1.	Mechanism of formation/configuration	142
6.3.1.1.1.	Examination of probable shifts in frequency bands of pertinent functional moieties	143
6.3.1.1.2.	Changes in thermal quantities due to the application of heat energy	147
6.3.1.1.3.	Gravimetric changes of samples during the process of fabrication of the P-RPM formulation	153
6.3.1.1.4.	Textural analysis of matrix physicochemical strength	154
6.3.1.2.	Mechanism of function/action	156
6.3.1.2.1.	Assessment of possible structural deformations during the process of matrix performance	156
6.3.1.2.2.	Evaluation of matrix surface morphology over time of exposure	159
6.3.1.2.3.	Matrix gravimetric changes due to hydration	160
6.3.1.2.4.	Matrix textural alterations	162
6.3.2.	The application of computational modeling to elucidating the mechanisms of configuration and function of the P-RPM formulation	165
6.3.2.1.	Prediction of the mechanism of formation/configuration	165
6.3.2.2.	Proposed mechanism of function/action	169
6.3.2.3.	Energy paradigms	170
6.4.	Concluding remarks	171
7.0.	Exploring the Influence of Scale-Up Processes and Common Environmental Storage Conditions on the Overall Physicochemical/Physicochemical Properties and Stability of the Optimized Pore-Regulated Polymer Matrix Formulation: A Preliminary Pilot Scale Investigation	
7.1.	Introduction	173

7.2.	Experimental section	174
7.2.1.	Materials	174
7.2.2.	Evaluation of the influence of scale-up processes on the physicochemical and physicomechanical properties of the optimized P-RPM formulation	174
7.2.3.	Assessment of the impact of common storage conditions on the stability of the optimized P-RPM formulation	175
7.3.	Results and discussion	177
7.3.1.	Effect of scale-up processes on the performance of the P-RPM formulation	177
7.3.2.	The influence of common environmental storage conditions on the stability of the P-RPM formulation	181
7.4.	Concluding remarks	184
8.0.	Conclusions and Recommendations	
8.1.	Conclusions	186
8.2.	Recommendations	188
	References	191
	Appendices	
	A: Abstract of journal publication	214
	B: Abstracts of conference proceedings	215
	C: University of the Witwatersrand animal ethics clearance certificate	223

LIST OF FIGURES

Figure	Title	Page
1.1.	A diagrammatic representation of a typical porous matrix showing the pore structures, interconnectors and component solid particles	5
1.2.	General structure of the buccal mucosa	14
1.3.	Chemical structures of (a) Phenytoin sodium and (b) Carbamazepine	17
1.4.	Phases involved in the fabrication of the drug loaded pore-regulated matrices	20
2.1.	Typical force-distance curve of a pore-regulated matrix for determining both: (a) peak detachment force and (b) work of adhesion(N = 3 in all cases)	35
2.2.	Typical force-distance and force-time profiles of the P-RPM formulation for determining (a) matrix firmness and energy of matrix distortion and (b) matrix resilience (N=3 in all cases)	38
2.3.	Calibration curves of PS in (a) simulated saliva (pH 6.8) and (b) simulated plasma (pH 7.4) at 206nm (N=3 and Standard Deviation ≤ 0.05 in all cases)	40
2.4.	Typical digital photographs of pore regulated matrices with convex-shaped base and flat surface	42
2.5.	A representation of inter-formulation and intra-formulation weight variations and similarities respectively (N = 3, Standard Deviation ≤ 1.80 mg)	43
2.6.	Drug release profiles for the 15 formulations in simulated saliva (pH 6.8) prior to optimization (N=3 and Standard Deviation $\leq 4.56\%$ in all cases)	46
2.7.	Cumulative quantity of PS that diffused through the porcine buccal mucosa into the receptor compartment in 8 hours (N = 3 and Standard Deviation $\leq 1.41\%$ in all cases)	48
2.8.	Cumulative steady state flux values computed over 8 hours for the 15 formulations (N = 3 and Standard Deviation $\leq 1.99 \times 10^{-4}$ mg cm ⁻² min ⁻¹ in all cases)	49
2.9.	Linear relationship between the percentage amount of permeated drug and flux	50
2.10.	Depiction of the permeability coefficient values for the 15 formulations (N=3 and Standard Deviation $\leq 1.02 \times 10^{-4}$ cm min ⁻¹ in all cases)	50
2.11.	Numerical values of: (a) Peak detachment force in Newton and (b) Work or energy of bioadhesion in Joules of the 15 formulations (N = 3 and in all cases)	52
2.12.	Qualitative measurement of porosity for the P-RPMs (N = 3 and in all cases)	53
2.13.	Typical porosimetric profiles showing the adsorption and desorption (a)	54

	isotherms, (b) BJH cumulative pore volume, (c) BJH cumulative pore surface area, (d) t-plot depicting the absence of micropores within the matrix (N = 3 and in all cases)	
2.14.	Typical scanning electron micrographs of the porous matrices showing the diversity of their pore structures, distributions and interconnectors (magnification 1000×)	58
2.15.	Typical profile showing the relationship between viscosity, shear stress and shear rate for the co-particulate homogenous blends (before lyophilization and freezing)	59
2.16.	Ranges of mean viscosity values generated by the homogenous blends of the 15 formulations at a constant shear rate (N = 3 and Standard Deviation $\leq 0.002 \times 10^4$ Pa.s in all cases)	60
2.17.	Deformation magnitudes of the homogenous blends of the 15 formulations at a constant shear rate (N = 3 in all cases)	61
2.18.	Graphical representation showing the direct or indirect linear mathematical relationships between average pore diameter and: (a) mean dissolution time, (b) cumulative drug permeation, (c) peak force of detachment, (d) drug loading capacity, (e) matrix resilience and (f) viscosity	66
2.19.	Graphical representation showing the direct or indirect linear mathematical relationships between cumulative surface area of pores and: (a) mean dissolution time, (b) cumulative drug permeation, (c) peak force of detachment, (d) drug loading capacity, (e) matrix resilience and (f) viscosity	67
3.1.	Calibration curves of CBZ in (a) simulated saliva (pH 6.8) and (b) simulated plasma (pH 7.4) at 285nm (N=3 and Standard Deviation ≤ 0.029 in all cases)	74
3.2.	Calibration curves of: (a) PS in pH 6.8 buffer media, (b) PS in pH 1.2 buffer media at 206nm and (c) CBZ in pH 6.8 buffer media, (d) CBZ in pH 1.2 buffer media at 285nm (N=3 and Standard Deviation ≤ 0.051 in all cases)	78
3.3.	Digital photographs showing the similarity in physical appearance of the optimized PS and CBZ loaded P-RPM formulations	79
3.4.	Scanning electron micrographs of the (a) PS and (b) CBZ optimized P-RPM formulations showing the characteristic pore structures, distributions and interconnectors (magnification 1000×)	81
3.5.	Fractional release profiles for PS and CBZ in simulated saliva, pH 6.8 over 8 hours (N = 3 and Standard Deviation ≤ 0.055 in all cases)	82
3.6.	Permeation of PS and CBZ molecules into simulated plasma, pH 7.4 through the porcine buccal mucosa over 8 hours (N = 3 and Standard Deviation ≤ 5.77 % in all cases)	85

3.7.	Changes in steady state flux with time over 8 hours (N = 3 and Standard Deviation $\leq 2.01 \times 10^{-4} \text{ mg cm}^{-2} \text{ min}^{-1}$ in all cases)	85
3.8.	Changes in permeability coefficient with time over 8 hours (N = 3 and Standard Deviation $\leq 3.99 \times 10^{-3} \text{ mg cm}^{-2} \text{ min}^{-1}$ in all cases)	86
3.9.	Drug release profiles of the optimized P-RPM formulation loaded with PS in simulated saliva (pH 6.8) compared with those of Epanutin [®] in 25mL simulated saliva (pH 6.8), 900mL simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 6.8) (N = 3 and Standard Deviation $\leq 5.67\%$)	88
3.10.	Drug release profiles of the optimized P-RPM formulation loaded with CBZ in simulated saliva (pH 6.8) compared with those of Tegretol [®] CR 25mL in 25mL simulated saliva (pH 6.8), 900mL simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 6.8) (N = 3 and Standard Deviation $\leq 7.02\%$)	89
4.1.	Digital photographs showing: (a) pig after intramuscular anaesthesia using midazolam and ketamine; (b) maintenance of anaesthesia employing isoflourane and oxygen by inhalation	98
4.2.	Digital photographs taken from different angles showing the placement of the P-RPM formulation in the non-keratinized region of the pig's oral cavity by veterinary experts	98
4.3.	Photographs showing the suturing process which resulted in the formation of a mucosal pouch which held the P-RPM formulation in place to prevent the pig from chewing or swallowing it	99
4.4.	Photographs showing the insertion of gastric tubing for passing the commercially available tablet oral formulations of CBZ (Tegretol [®] CR) and PS (Epanutin [®]) into the stomach	99
4.5.	A schematic of WinNonlin [®] compiled non-compartmental pharmacokinetic model of plasma concentration of drug versus time via extravascular administration from the drug loaded P-RPM formulation	103
4.6.	A schematic of WinNonlin [®] compiled pharmacodynamic model for drug effect data estimation of the P-RPM formulation	103
4.7.	Three-dimensional UPLC chromatogram of (a) PS with its internal standard, amitriptyline hydrochloride and (b) CBZ with its internal standard, theophylline	106
4.8.	Calibration curves of (a) PS in plasma using amitriptyline hydrochloride as an internal standard at 214nm and (b) CBZ in plasma using theophylline as an internal standard at 285nm (N=3 and Standard Deviation ≤ 0.35 in all cases)	107
4.9.	Plasma concentration versus time profile for the PS (50mg) loaded P-RPM formulation and Epanutin [®] (100mg) (N=6)	108

4.10.	Plasma concentration versus time profile for the CBZ (50mg) loaded P-RPM formulation and Tegretol®CR (200mg) (N=6)	109
4.11.	Profiles showing the close relationships between the observed and fitted plasma concentration-time data of: (a) PS released from the P-RPM, (b) PS released from the Epanutin®, (c) CBZ released from the P-RPM and (d) CBZ released from the Tegretol®CR (N=5 and Standard Deviation ≤ 0.10 in all cases)	111
4.12.	Relative residual plots obtained for fitted plasma drug concentration-time data employing the non-compartmental PK-PD model for the (a) PS loaded P-RPM and Epanutin® and (b) CBZ loaded P-RPM and Tegretol®CR formulations based on the first order rate constant associated with the terminal portion of the curve (N=5 in all cases)	112
4.13.	An illustration of the cumulative increase in PS concentration over a period of 24 hours computed from: (a) AUC and (b) AUMC of the mean <i>in vivo</i> concentration-time profiles of the PS loaded P-RPM formulation and the comparator product, Epanutin®	115
4.14.	An illustration of the cumulative increase in CBZ concentration over a period of 24 hours computed from: (a) AUC and (b) AUMC of the mean <i>in vivo</i> concentration-time profiles of the CBZ loaded P-RPM formulation and the comparator product, Tegretol®CR	115
4.15	A point-to-point level A IVIVC model plot for the PS loaded P-RPM formulation	116
4.16	A point-to-point level A IVIVC model plot for the CBZ loaded P-RPM formulation	117
4.17	FTIR spectra showing the qualitative analysis of PS plasma levels over time in comparison with blank plasma and the pure drug	118
4.18	FTIR spectra showing the qualitative analysis of CBZ plasma levels over time in comparison with blank plasma and the pure drug	120
5.1.	Calibration curves for (a) CACO-2, (b) HT-29 and (c) MCF-7 cell cultures for MTT colorimetric assay	128
5.2.	Micrographs of the normal porcine buccal epithelium with no formulation or suture applied (control) (x40)	130
5.3.	Micrographs of the sutured porcine buccal epithelium with no formulation applied (x40).	131
5.4.	Micrographs of the porcine buccal epithelium after removal of minute remnants of the placebo (drug-free) loaded pore-regulated formulation (x40)	131
5.5.	Micrographs of the porcine buccal epithelium after removal of minute remnants of the PS loaded pore-regulated formulation (x40)	132

5.6.	Micrographs of the porcine buccal epithelium after removal of minute remnants of the CBZ loaded pore-regulated formulation (x40)	132
5.7.	A graphical representation of the percentage cell viability after a 48 hour separate exposure to the PS and CBZ loaded P-RPM formulation relative to the positive and negatives controls using the CACO-2 cell culture	134
5.8.	A graphical representation of the percentage cell viability after a 48 hour separate exposure to the PS and CBZ loaded P-RPM formulation relative to the positive and negative controls using the HT-29 cell culture	134
5.9.	A graphical representation of the percentage cell viability after a 48 hour separate exposure to the PS and CBZ loaded P-RPM formulation relative to the positive and negatives controls using the MCF-7 cell culture	135
6.1.	FTIR spectra of the optimized, un-lyophilized co-particulate homogenous blend loaded with PS	146
6.2.	FTIR spectra of the optimized, lyophilized P-RPM formulation loaded with PS	146
6.3.	Different thermograms of the un-lyophilized homogenous co-particulate blend showing the: (a) C-DSC curve, (b), (c), (d) and (e) TM-DSC curves with the endothermic and exothermic peaks generated from the reversible, non-reversible and total heat flows at varying temperature ranges	149
6.4.	Diversified thermograms of the lyophilized P-RPM formulation showing the: (a) C-DSC curve, (b) and (c) TM-DSC curves with the endothermic and exothermic peaks generated from the reversible, non-reversible and total heat flows at specific temperature cycles	150
6.5.	Quantification of gravimetric weight changes at strategic points during the fabrication of the P-RPM formulation (n = 3 and Standard Deviation $\leq$ 8.95mg in all cases)	153
6.6.	Superimposed FTIR spectra of the hydrated and unhydrated P-RPM formulations	156
6.7.	Scanning electron micrographs showing the changes in matrix surface geometry over the duration of hydration	159
6.8.	Changes in matrix fractional mass over the duration of exposure to the dissolution medium (n = 3 and Standard Deviation $\leq$ 0.02 in all cases)	161
6.9.	Linear relationship between fractional drug release and fractional mass loss	161
6.10.	Changes in matrix physicomechanical texture due to hydration: (a) Matrix firmness and (b) Energy of matrix distortion	162
6.11.	Textural analysis profiles showing the changes in matrix physicomechanical texture over time due to hydration	164
		165

6.12.	A computationally modeled illustration of the processes of formation of the drug-loaded homogenous co-particulate blend showing: (a) different polymer's strands, scattered solvent molecules (stars) in independent hydrophilic interactions, (b) the presence of the drug molecules (squared dots), associations of drug with the gelatin molecules (eccentric circular dots) and solutes particles in the mixed medium containing ethanol (free space/void), (c) a drug loaded homogenous blend before freeze-drying	
6.13.	A computationally modeled three-dimensional mesh showing interaction between the solvent centres (red circles) and solute strands (greenish circles) forming hydrophilic-natured pockets (whitish spaces)	166
6.14.	Computationally modeled depiction of layering due to strong hydrophilic solute-solvent interactions (Region A) and scattered solvent molecules (Region B) around lesser affinity groups, molecules, polymers and drugs	167
6.15.	Computationally modeled representation of solute-solvent interactions resulting in the formation of cavities (whitish, asymmetric circular portions within the network labeled 'c')	167
6.16.	Computationally modeled illustration of multiple solute strands in interaction with solvent molecules resulting in the evolution of inter-strand, multiple cavities (labeled 'c')	168
6.17.	A computationally modeled schematic showing the formation of interconnected cavities forming the channels: (a) drug-loaded, homogenized blend, (b) multiple strands undergoing physicochemical interactions along with drug molecules (as squared dots), (c) physicochemical interactive associations (represented as broken and solid lines) between solute-solute strands interconnectors, (d) a foot-print view of the associations and channel cavity and (e) a three-dimensional view of inter-strand networked channels (ordered porous structure) with drug molecules loaded unto the matrix	168
6.18.	Computational models showing the construction of the drug loaded P-RPM formulation: (a) drug loaded water-based co-particulate dispersion showing several solute strands, drug molecules (colored circles) undergoing hydrophilic physicochemical interactions (white circles) and molecules of the water (star-shaped entities) scattered within the matrix, (b) the ethanol based co-particulate dispersion with the solutes depicted as broken lines and elongated double lines, ethanol molecules as y-shaped figurines scattered in the preparatory matrix, (c) a mixture of (a) and (b) with span 80 (reduction of interfacial tension) to form the homogenous co-particulate blend characterized by as increased volume density of the constituents, (d)	169

	the freeze-dried or lyophilized matrix devoid of free floating water, water pockets, ethanol and ethanol-water associative entities which gave rise to a homogenized and ordered porous matrix showing solute strands from both the water-based and ethanol-based co-particulate dispersions origins as well as evenly distributed drug molecules and other associated adds-up of the blend (physical interaction)	
6.19.	A computationally modeled compressive disruption of the ordered porous structure	170
6.20.	The: (a) Qualitative representation of averaged typical energy, E against time, T of the porous matrix (solid line) and energy of the homogenized blend (broken lines), (b) Energy decay over time in a regressive pattern	170
7.1.	Drug release profiles comparing Batch A (laboratory scale) with the scale-up (Batches B and C) formulations (N = 3 and Standard Deviation $\leq 4.92\%$ in all cases)	179
7.2.	Comparison of the permeation of PS molecules through the porcine buccal mucosa over 8 hours for the laboratory scale and scale-up formulations (N = 3 and Standard Deviation $\leq 4.02\%$ in all cases)	180
7.3.	Scanning electron micrographs showing the surface porous structure of the laboratory scale and scale-up P-RPM formulations (magnification 1000 $\times$)	181

LIST OF TABLES

Table	Title	Page
2.1.	The role of/rationale for selecting each compound employed in the construction of the P-RPMs	29
2.2.	Levels of the independent variables employed in the Box-Behnken design template	29
2.3.	Box-Behnken template for the preparation of each pore-regulated polymer matrix	30
2.4.	Textural settings employed for the determination of matrix resilience, energy of matrix distortion and matrix firmness	38
2.5.	Numerical targets set for the selected response parameters	41
2.6.	Levels of statistical significance of the response parameters employing ANOVA	41
2.7.	MDT _{50%} values depicting the drug release characteristics of the 15 formulations	45
2.8.	Percentage drug loading capacity for the 15 formulations	47
2.9.	The numerical values of the quantitative porosimetric measures	56
2.10.	Matrix resilience, distortion and firmness numerical values for the P-RPMs	63
2.11.	Levels of solute and solvent components for the fabrication of the optimized P-RPM	63
2.12.	Comparison of the fitted and experimental values of the response parameter to assess the efficiency of the experimental design for formulation optimization	64
3.1.	Some physicochemical measures highlighting possible similarities and differences between the PS and CBZ loaded formulation matrices	80
3.2.	Parameters utilized to capture and compare the drug release performances of the PS and CBZ loaded matrix formulations	83
3.3.	Parameters utilized to capture and compare the drug release performances of the PS and CBZ loaded matrix formulations	87
3.4.	Computed difference and similarity factors to compare the drug release performances of the P-RPM formulations with the commercially available products	89
3.5.	Employing the difference and similarity factors to compare the drug release behaviour of the commercially available products subjected to different dissolution conditions	90
4.1.	Diagnostic numerical criteria employed for the assessment of the PK-PD model goodness-of-fit	110

4.2.	Comparative summary of estimated pharmacokinetic parameters for the PS and CBZ loaded P-RPM formulations and their conventional formulations (N=5)	113
4.3	Comparative summary of estimated pharmacodynamic parameters for the effect of the PS and CBZ loaded P-RPM formulations and their conventional formulations (N=5)	114
5.1.	Summary of histopathological state of buccal mucosal specimens collected	130
6.1.	A presentation of the vibrational frequencies and functional moieties of the respective pure compounds constituting the P-RPM	145
6.2.	Measured glass transition and melting temperature values for the pure compounds employed in the fabrication of the P-RPM formulation using C-DSC	147
6.3.	Temperature changes revealing salient multi-transitional thermal events evidenced by diverse endothermic and exothermic inflection peaks	151
6.4.	Values of physicochemical parameters measured utilizing samples generated during the preparation of the P-RPM formulation	154
6.5.	Shifts in the vibrational frequencies of relevant functional moieties of the hydrated samples with the unhydrated P-RPM formulation as a reference point	158
7.1.	Formulation composition for the laboratory scale and scale-up sets of formulations	171
7.2.	Influence of scale-up processes on the physicochemical properties of the optimized P-RPM formulation	178
7.3.	The difference factor values generated to compare the drug release behaviour of the laboratory scale and scale-up formulations	179
7.4.	Physicochemical and physicochemical parameters measured for assessing the stability of the P-RPM formulation over the specified storage duration and conditions	182